SCHEMBL7711322

SCHEMBL7711322

CC1Oc2ccc(C(Cc3ccc4c(c3)OCO4)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 4/20 0.35
KDM4E B2RXH2 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
POLB P06746 1/20 0.34
FPR1 P21462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710382 0.91 PARP1 (0.40) MEN1KMT2ASMN1; SMN2CYP3A4KDM4E
SCHEMBL7095640 0.88 ALDH1A1 (0.37) MEN1KMT2ASMN1; SMN2KDM4ERAB9A
SCHEMBL7091267 0.87 HSD17B10 (0.33) MEN1KMT2ASMN1; SMN2KDM4ERAB9A
SCHEMBL7087725 0.87 CTSS (0.41) MEN1KMT2ASMN1; SMN2RAB9AHPGD
SCHEMBL7092472 0.87 HSD17B10 (0.37) MEN1KMT2ASMN1; SMN2RAB9AHPGD
SCHEMBL7704943 0.87 ALDH1A1 (0.43) MEN1KMT2ASMN1; SMN2RAB9AHPGD
SCHEMBL7094044 0.86 SMN1; SMN2 (0.40) MEN1KMT2ASMN1; SMN2RAB9AHPGD
SCHEMBL7092669 0.86 CTSS (0.34) MEN1KMT2ASMN1; SMN2KDM4ERAB9A
SCHEMBL7711070 0.85 CACNA1B (0.40) MEN1KMT2ASMN1; SMN2RAB9AHPGD
SCHEMBL7090483 0.85 CTSS (0.45) MEN1KMT2ASMN1; SMN2KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed